Evaluation of the Influence of the Conjugation Site of the Chelator Agent HYNIC to GLP1 Antagonist Radiotracer for Insulinoma Diagnosis

Author(s): Bluma Linkowski Faintuch, Daniele Seo, Erica Aparecida de Oliveira, Roselaine Campos Targino, Ana Maria Moro

Journal Name: Current Radiopharmaceuticals

Volume 10 , Issue 1 , 2017

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background and Objective: Radiotracer diagnosis of insulinoma, can be done using somatostatin or glucagon-like peptide 1 (GLP-1). Performance of GLP-1 antagonists tends to be better than of agonists.

Methods: We investigated the uptake of the antagonist exendin (9-39), radiolabeled with technetium- 99m. Two different sites of the biomolecule were selected for chelator attachment.

Results: HYNIC-βAla chelator attached to serine (C- terminus) of exendin, was associated with higher tumor uptake than to aspartate (N- terminus).

Conclusion: The chelator position in the biomolecule influenced receptor uptake.

Keywords: Insulinoma, GLP-1, antagonist, exendin (9-39), radiotracer, Technetium-99m.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Published on: 07 March, 2017
Page: [65 - 72]
Pages: 8
DOI: 10.2174/1874471010666170126143636
Price: $65

Article Metrics

PDF: 13